Additional file 1 of Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis

Additional file 1: Table S1. Increases in immune cell types or functions lacking statistically significant associations with risk of Gd+ and T2 lesions, with an exception for CD3+CD8+CXCR3+ T cells and T2 lesions (in bold type). Figure S1. Typical patterns of changes in lymphocyte and monocyte counts assessed every six months following alemtuzumab treatment in whole blood assessed in clinical TBNK assays. Figure S2. Expanded characteristics of Treg phenotypes in PBMC. Figure S3. Changes in naïve and memory CD4+ T cell subsets in whole blood following alemtuzumab treatment. Figure S4. Changes in cytokine secretion patterns in PBMC. Figure S5. Analyses of additional lymphocyte subsets stratified for active vs stable disease or presence and absence of secondary autoimmune disease. Figure S6. Lack of significant differences in percentages of CD4+CD25+CD127+foxP3- Teff cells stratified for patients with and without relapses (top three panels) or evidence of lesion activity on MRI (bottom three panels).